麻豆传媒

Trusted by:

clients clients clients clients clients clients clients clients clients clients
Release date: 27-Apr-2025 6:05 PM EDT
Pretrained Machine Learning Models May Help Accurately Diagnose Nonmelanoma Skin Cancer in Resource-limited Settings
University of Chicago Medical Center

Artificial intelligence models, pretrained on vast datasets, significantly outperformed a standard baseline model in identifying nonmelanoma skin cancers (NMSC) from digital images of tissue samples, according to research presented at the American Association for Cancer Research (AACR) Annual Meeting, held April 25-30.

麻豆传媒: 0141ef25-4f20-4c2e-b86d-9b2af
24-Apr-2025 6:10 AM EDT
EMBARGOED: Social 鈥楬ippie鈥 Spiders Don't Believe in Labels
University of Portsmouth

Study raises the question of whether social 鈥榟ippie鈥 spiders truly have personalities at all Individual behaviour in spider communities far more fluid than previously thought Instead of fixed behavioural types, spiders appear to adjust their behaviour dynamically based on circumstances

麻豆传媒: AACR: First-in-class covalent Werner helicase inhibitor shows clinical proof-of-concept in Phase I trial
26-Apr-2025 2:30 PM EDT
AACR: First-in-class covalent Werner helicase inhibitor shows clinical proof-of-concept in Phase I trial
University of Texas MD Anderson Cancer Center

鈥 RO7589831, a new drug from Roche, is first in a new class of drugs called Werner helicase inhibitors 鈥 Drug works similarly to other DNA damage repair inhibitors, such as PARP inhibitors 鈥 This class of drugs is important because many solid tumor patients with microsatellite instability (MSI) do not benefit from currently approved immunotherapies 鈥 Encouraging early results in this first-in-human trial prompted additional trial cohorts to optimize recommended dose for future clinical development

麻豆传媒: AACR: Topical gel relieves painful skin rash side effect caused by targeted therapy for colorectal cancer
26-Apr-2025 2:55 PM EDT
AACR: Topical gel relieves painful skin rash side effect caused by targeted therapy for colorectal cancer
University of Texas MD Anderson Cancer Center

路 LUT014, a topical BRAF inhibitor made by Lutris Pharma, is the first agent to treat the cause of the rash without interfering with the treatment itself 路 Over two-thirds of patients had successful treatment with the higher dose of LUT014 compared to one-third with placebo

25-Apr-2025 11:05 AM EDT
AACR: Topical Treatment Offers Relief From Painful Skin Rash Caused by Targeted Cancer Therapy
University of California, Los Angeles (UCLA), Health Sciences

UCLA researchers demonstrated that a novel topical BRAF inhibitor gel called LUT014 significantly reduces the severity of an acne-like rash, a common and painful side effect experienced by patients undergoing anti-EGFR therapies for colorectal cancer.

Release date: 27-Apr-2025 2:45 PM EDT
Immunotherapy Could Replace Surgery, Enabling Patients To Retain Their Organs and Enhance Their Quality of Life
Memorial Sloan Kettering Cancer Center

New results from a clinical trial led by Memorial Sloan Kettering Cancer Center (MSK), demonstrate how immunotherapy alone can allow people with MMRd cancers to avoid surgery and preserve their quality of life. The results, presented at the 2025 American Association of Cancer Research (AACR) Annual Meeting and published simultaneously in The New England Journal of Medicine (NEJM), found that 80 percent of patients did not require surgery, radiation, or chemotherapy after six months of treatment with immunotherapy alone.

麻豆传媒: AACR: Olaparib and pembrolizumab combination shows early promise in molecularly selected, tumor-agnostic trial
26-Apr-2025 2:55 PM EDT
AACR: Olaparib and pembrolizumab combination shows early promise in molecularly selected, tumor-agnostic trial
University of Texas MD Anderson Cancer Center

鈥 Combining Lynparza (olaparib) and Keytruda (pembrolizumab) showed antitumor activity in multiple cancer types, particularly those with BRCA1/2 mutations 鈥 Combination demonstrated complete responses and partial responses in different cancer types, including those beyond the currently approved indications for these therapies

Release date: 27-Apr-2025 1:40 PM EDT
Moffitt Study Uncovers a Way to Boost Treatment for Aggressive Melanoma
Moffitt Cancer Center

A new study from researchers at Moffitt Cancer Center shows that blocking a chemical process called nitrosylation could make one of the most aggressive forms of melanoma more treatable.

26-Apr-2025 12:00 AM EDT
Immunotherapy improves survival of patients with locally advanced head and neck cancer
Washington University in St. Louis

An international phase 3 clinical trial led by Washington University School of Medicine in St. Louis and Dana-Farber Brigham Cancer Center shows that patients with certain locally advanced head and neck cancers benefited from the addition of the immunotherapy drug pembrolizumab (brand name Keytruda) to standard-of-care therapy. Patients who received pembrolizumab saw greater tumor shrinkage prior to surgery and, on average, survived cancer-free almost two years longer than did patients who only received standard-of-care therapy.

麻豆传媒: Immunotherapy Before and After Surgery Improves Outcomes in Head and Neck Cancer
Released: 27-Apr-2025 12:00 PM EDT
Immunotherapy Before and After Surgery Improves Outcomes in Head and Neck Cancer
Dana-Farber Cancer Institute

Patients with locally advanced head and neck cancer who received the immune checkpoint inhibitor pembrolizumab before, during and after standard-of-care surgery had longer event-free survival without the cancer coming back and higher rates of substantial tumor shrinkage prior to surgery, according to the first interim analysis of a randomized, open-label phase 3 clinical trial led by investigators from Dana-Farber Brigham Cancer Center and Washington University School of Medicine in St. Louis.


close
1.31802